Kyowa Hakko President Yuzuru Matsuda : Speed is Key in Growing Globally
This article was originally published in PharmAsia News
In an interview with Yakuji News, Kyowa Hakko President Yuzuru Matsuda said the company was moving faster to compete globally and achieve market leadership in antibody drugs. The antibody drug market reached ¥2,200 billion last year and is estimated to reach ¥4,500 billion by 2011. A merger with Kirin Pharma is expected to create synergy for the two companies that combine Kyowa's Potelligent technology and Kirin's KM mouse technology for creating humanized antibodies. This will boost efficiency in R&D and speed up new drug development, which Matsuda said was key for Kyowa. The company has three drugs in clinical trials: Kyowa's CCR4 antibody-KW-076, Medimmune's receptor antibody-BIW-8405, and Medarex's CD 30 antibody-MDX-1401. (Click for more-Japanese language
You may also be interested in...
Teligent has achieved a “pivotal step in our journey toward securing a strong financial future,” according to management, after recapitalizing its significant debt burden and gaining access to more cash.
Pfizer has entered into an agreement with Premier to supply five essential medications to US healthcare providers through Premier’s ProvideGx program. Both companies aim to secure supply of products specifically used by COVID patients.
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.